Core Points - Indaptus Therapeutics, Inc. has announced a one-for-twenty-eight reverse stock split of its common stock, effective after trading closes on June 26, 2025 [1] - The reverse stock split aims to increase the per share price and bid price to regain compliance with Nasdaq listing requirements and attract institutional investors [1] - Following the split, the number of outstanding shares will decrease from approximately 16 million to about 572 thousand [3] Stockholder Impact - Every 28 shares will be converted into one share, with adjustments made to the exercise price and number of shares for outstanding options and warrants [2] - No fractional shares will be issued; instead, stockholders will receive cash payments for any fractional shares based on the adjusted closing price on June 26, 2025 [3] - Registered stockholders in book-entry form do not need to take action, while those with physical certificates will receive instructions for exchanging them [4] Additional Information - More details about the reverse stock split can be found in the definitive proxy statement filed with the SEC on April 28, 2025 [5]

Core Viewpoint - Cellectar Biosciences, Inc. announced a one-for-thirty reverse stock split effective June 24, 2025, aimed at consolidating shares to potentially enhance stock performance and meet listing requirements on Nasdaq [1][2]. Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing drugs for cancer treatment, utilizing its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform [7]. Reverse Stock Split Details - The reverse stock split was approved by stockholders on June 13, 2025, reducing the number of shares from approximately 54.36 million to about 1.81 million [2]. - Each stockholder's percentage ownership will remain unchanged, except for fractional shares, which will be compensated in cash [3]. - The reverse stock split will proportionately affect the number of shares available under equity incentive plans and adjust the terms of outstanding stock options and warrants accordingly [4]. Administrative Aspects - Equiniti Trust Company, LLC will act as the transfer agent for the reverse stock split, managing the issuance of post-split shares without requiring action from stockholders [5]. - Additional information regarding the reverse stock split is available in the company's definitive proxy statement filed with the SEC [6]. Product Pipeline - Cellectar's product pipeline includes iopofosine I 131, which has received Breakthrough Therapy Designation from the FDA, and other programs targeting various solid tumors [8][10]. - The company is also developing CLR 121225 and CLR 121125, targeting significant unmet needs in cancer treatment [8][9].

A reverse stock split consolidates the number of existing shares of corporate stock into fewer—and proportionally more valuable—shares. https://t.co/MSmqms8udw ...

Core Points - KULR Technology Group, Inc. will implement a 1-for-8 reverse stock split effective June 23, 2025, to optimize market dynamics and broaden investor appeal [1][2][3] - The reverse stock split will reduce the number of outstanding shares from approximately 300 million to less than 40 million [4] Company Strategy - The reverse stock split aims to position KULR for broader institutional participation and enhance long-term shareholder value, particularly in light of the upcoming Russell 3000 Index reconstitution [3] - The company believes that a higher share price will facilitate inclusion in institutional portfolios and trading platforms with minimum price thresholds [3] Stockholder Impact - The reverse stock split will not change the par value of KULR's common stock, which remains at $0.0001 per share, and will not alter any stockholder's percentage interest in the company's equity, except for fractional shares [3] - Fractional shares will not be issued; instead, stockholders will receive additional shares to round up to a full share [3] Company Overview - KULR Technology Group is a Bitcoin First Company specializing in energy storage solutions for space, aerospace, and defense, leveraging in-house battery design and production capabilities [6] - Since late 2024, KULR has included bitcoin as a primary asset in its treasury program, committing to allocate up to 90% of its cash for bitcoin acquisition [6]

Core Viewpoint - Sensei Biotherapeutics, Inc. is implementing a 1-for-20 reverse stock split to comply with Nasdaq Capital Market's minimum bid price requirement, effective June 16, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of issued and outstanding shares from approximately 25.2 million to about 1.3 million [3]. - The authorized shares will decrease from 250 million to 12.5 million [3]. - Fractional shares will not be issued; instead, stockholders entitled to fractional shares will receive a cash payment [4]. Group 2: Trading Information - The common stock will begin trading on a split-adjusted basis on June 17, 2025, under the existing trading symbol "SNSE" [2]. - Equiniti Trust Company, LLC will act as the exchange agent and transfer agent for the reverse stock split [5]. Group 3: Company Overview - Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer patients through its TMAb™ platform [6]. - The lead product candidate, solnerstotug, is designed to block the VISTA checkpoint selectively within the tumor microenvironment [6].

Core Viewpoint - FibroGen, Inc. will implement a 1-for-25 reverse stock split to increase the per-share market price and regain compliance with Nasdaq listing requirements [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective at 5:00 p.m. Eastern Time on June 16, 2025, with trading on a split-adjusted basis starting June 17, 2025 [1]. - The number of issued and outstanding shares will decrease from approximately 101.1 million to about 4.0 million shares [3]. - Stockholders will receive cash payments for any fractional shares instead of receiving fractional shares [3]. Group 2: Approval and Purpose - The reverse stock split was approved by stockholders at the 2025 Annual Meeting held on June 4, 2025 [2]. - The primary goal of the reverse stock split is to increase the market price of FibroGen's common stock to meet Nasdaq's minimum bid price requirement [2]. Group 3: Company Overview - FibroGen is a biopharmaceutical company focused on developing novel therapies for cancer and anemia [5]. - Roxadustat is approved in multiple regions for treating anemia in chronic kidney disease patients [5]. - The company is also developing FG-3246, an antibody-drug conjugate for metastatic castration-resistant prostate cancer [5].

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-60 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001 per share (t ...

Group 1 - AIM ImmunoTech Inc. announced a reverse stock split at a ratio of 1-for-100, effective June 12, 2025 [1] - The primary goal of the reverse stock split is to increase the per-share market price to regain compliance with NYSE American's Listing Qualifications [2] - Stockholders approved the reverse stock split at a Special Meeting on April 30, 2025, and will receive cash for any fractional shares post-split [3] Group 2 - AIM ImmunoTech Inc. focuses on the research and development of therapeutics for cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), an investigational drug with broad-spectrum activity in clinical trials [4]

Core Viewpoint - Onconetix, Inc. has announced a reverse stock split of 1-for-85 shares, approved by stockholders, to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, effective June 13, 2025 [1][3][5] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 44.4 million to about 521,863 [5] - The split will be executed automatically, converting every 85 shares into one share without changing the par value, and no fractional shares will be issued [4] - Fractional shares will be compensated in cash based on the closing price on June 12, 2025 [4] Group 2: Company Overview - Onconetix, Inc. is a commercial-stage biotechnology company focused on men's health and oncology, owning products like Proclarix and ENTADFI [6] - Proclarix is an in vitro diagnostic test for prostate cancer, while ENTADFI is an FDA-approved treatment for benign prostatic hyperplasia [6]

Core Viewpoint - Artelo Biosciences, Inc. has announced a 6-for-1 reverse stock split to increase the price per share to meet Nasdaq's minimum listing requirement of $1.00 per share, effective June 13, 2025 [1][2]. Company Overview - Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions including cancer, pain, and dermatological issues [3]. - The company is advancing a portfolio of product candidates aimed at addressing significant unmet medical needs across multiple diseases [3]. Reverse Stock Split Details - The reverse stock split will automatically convert every six shares of the company's common stock into one share, maintaining shareholders' pro-rata ownership [2]. - Post-split, approximately 546,667 shares of common stock will be issued and outstanding [2].